Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
J Headache Pain Manag, 1, 2
It should be the headline
These processes take time
[DOI] [PMC free article] [PubMed] [Google Scholar] 52.Echevarria-Lima J
In the field of delivery technology, targeting the unique joint anatomy and pathological environment of OA, developing biodegradable sustained-release carriers such as smart responsive nanogels, porous microspheres, or tissue engineering scaffolds is key to achieving long-term and controlled release of GPX4 genes, regulatory miRNAs or ASOs, or small molecule ferroptosis inhibitors at the lesion site ( Considering the multifactorial pathogenesis of OA, future research needs to prioritize conducting early proof-of-concept clinical trials to evaluate the feasibility and synergistic effects of locally applied ferroptosis inhibitors such as Fer-1 or GPX4 activators combined with existing conservative treatments including weight management, physical therapy, and NSAIDs or emerging cell and tissue engineering therapies
